Home



News

Midazolam Nasal Spray (USL261) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters

Cambridge, UK – April 26, 2017 Proximagen Limited (Proximagen) today announced that its pivotal Phase 3 trial of intranasal midazolam (USL261) for the rescue treatment…

Read More

Proximagen to Become Wholly-Owned Subsidiary of ACOVA

Cambridge, UK – April 20, 2017 Proximagen’s parent company Upsher-Smith Laboratories, Inc. (Upsher-Smith), a business owned by the Evenstad family, today announced an agreement to…

Read More

Events

BioTrinity (UK) (23-25 April 2018)

http://www.life-sciences-europe.com/product/biotrinity-2018-london-obn-ltd-oxfordshire-bioscience-network-2001-25145.html

Read More

Bio Europe (12-14 March 2018)

http://www.life-sciences-europe.com/product/bio-europe-spring-2018-ebd-group-informa-gmbh-2001-25152.html

Read More